HZO Stock Analysis: MarineMax | NYSE
Specialty Retail | NYSE, USA | Market Cap: 1.153m USD | 12M Return: 89.2% | US5679081084 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 23.6M
EPS Trend: -94.8%
Qual. Beats: 0
Rev. Trend: -82.7%
Qual. Beats: -2
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
MarineMax, Inc. (NYSE: HZO) is a U.S.-based recreational boat and yacht retailer headquartered in Oldsmar, Florida. The company operates in two segments: Retail Operations and Product Manufacturing, selling new and used pleasure boats, fishing boats, yachts, pontoons, jet boats, and other recreational watercraft through its dealership network and offsite locations.
Beyond boat sales, MarineMax generates recurring revenue from marine parts and accessories, maintenance and repair services, slip and storage, brokerage, yacht charters, and power catamarans. It also offers customer financing and insurance products, including boat property, casualty, and undercoating coverage, and manufactures sport yachts through its production segment. The company additionally runs MarineMax Vacations in Tortola and the British Virgin Islands and sells branded novelty items such as apparel and license plates.
The recreational boating industry is a discretionary consumer category that tends to track with macroeconomic conditions, consumer confidence, and interest rates, which directly affect boat financing demand. MarineMax, classified under Consumer Discretionary / Other Specialty Retail, combines dealership, manufacturing, and service-based revenue streams, with the latter providing some insulation against the cyclicality of new and used boat sales. The company was incorporated in 1998.
- Interest rates cool demand for financed boat purchases
- Used boat inventory levels pressure retail gross margins
- Superyacht services and acquisitions diversify revenue mix
| Net Income: 3.98m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 9.70 > 1.0 |
| NWC/Revenue: 9.37% < 20% (prev 8.91%; Δ 0.46% < -1%) |
| CFO/TA 0.09 > 3% & CFO 219.0m > Net Income 3.98m |
| Net Debt (1.07b) to EBITDA (79.8m): 13.46 < 3 |
| Current Ratio: 1.23 > 1.5 & < 3 |
| Outstanding Shares: last quarter (22.8m) vs 12m ago 6.10% < -2% |
| Gross Margin: 34.21% > 18% (prev 32.41%; Δ 1.80% > 0.5%) |
| Asset Turnover: 90.63% > 50% (prev 93.27%; Δ -2.64% > 0%) |
| Interest Coverage Ratio: 1.08 > 6 (EBIT TTM 66.8m / Interest Expense TTM 62.1m) |
| A: 0.09 (Total Current Assets 1.09b - Total Current Liabilities 881.0m) / Total Assets 2.36b |
| B: 0.32 (Retained Earnings 751.2m / Total Assets 2.36b) |
| C: 0.03 (EBIT TTM 66.8m / Avg Total Assets 2.42b) |
| D: 0.68 (Book Value of Equity 952.5m / Total Liabilities 1.39b) |
| Altman-Z'' = 2.51 = A |
| DSRI: 0.89 (Receivables 95.1m/112.7m, Revenue 2.20b/2.32b) |
| GMI: 0.95 (GM 32.41% / 34.21%) |
| AQI: 1.04 (AQ_t 0.25 / AQ_t-1 0.24) |
| SGI: 0.95 (Revenue 2.20b / 2.32b) |
| TATA: -0.09 (NI 3.98m - CFO 219.0m) / TA 2.36b) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of August 27, 2026, the stock is trading at USD 52.11 with a total of 400,349 shares traded. Over the past week, the price has changed by -0.21%, over one month by +43.75%, over three months by +50.39% and over the past year by +89.15%.
Current recommended Stop Loss: 50.60 (which is 2.9% or 1.2 ATR below the current price).
MarineMax has received a consensus analysts rating of 4.56. Therefore, it is recommended to buy HZO.
- StrongBuy: 7
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 47 | -9.8% |
P/E Trailing = 326.25
P/E Forward = 34.3643
P/S = 0.525
P/B = 1.2104
P/EG = 1.0885
Revenue TTM = 2.20b USD
EBIT TTM = 66.8m USD
EBITDA TTM = 79.8m USD
Long Term Debt = 335.2m USD (from longTermDebt, last quarter)
Short Term Debt = 647.3m USD (from shortTermDebt, last quarter)
Debt = 1.25b USD (from shortLongTermDebtTotal, last quarter) + Leases 138.8m
Net Debt = 1.07b USD (calculated: Debt 1.25b - CCE 174.8m)
Enterprise Value = 2.23b USD (1.15b + Debt 1.25b - CCE 174.8m)
Interest Coverage Ratio = 1.08 (Ebit TTM 66.8m / Interest Expense TTM 62.1m)
EV/FCF = 12.51x (Enterprise Value 2.23b / FCF TTM 178.0m)
FCF Yield = 7.99% (FCF TTM 178.0m / Enterprise Value 2.23b)
FCF Margin = 8.11% (FCF TTM 178.0m / Revenue TTM 2.20b)
Net Margin = 0.18% (Net Income TTM 3.98m / Revenue TTM 2.20b)
Gross Margin = 34.21% ((Revenue TTM 2.20b - Cost of Revenue TTM 1.44b) / Revenue TTM)
Gross Margin QoQ = 35.68% (prev 34.37%)
Tobins Q-Ratio = 0.94 (Enterprise Value 2.23b / Total Assets 2.36b)
Interest Expense / Debt = 4.98% (Interest Expense 62.1m / Debt 1.25b)
Taxrate = 31.70% (7.26m / 22.9m)
NOPAT = 45.6m (EBIT 66.8m * (1 - 31.70%))
Current Ratio = 1.23 (Total Current Assets 1.09b / Total Current Liabilities 881.0m)
Debt / Equity = 1.31 (Debt 1.25b / totalStockholderEquity, last quarter 952.5m)
Debt / EBITDA = 13.46 (Net Debt 1.07b / EBITDA 79.8m)
Debt / FCF = 6.03 (Net Debt 1.07b / FCF TTM 178.0m)
Total Stockholder Equity = 938.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.16% (Net Income 3.98m / Total Assets 2.36b)
RoE = 0.42% (Net Income TTM 3.98m / Total Stockholder Equity 938.7m)
RoCE = 5.25% (EBIT 66.8m / Capital Employed (Equity 938.7m + L.T.Debt 335.2m))
RoIC = 2.26% (NOPAT 45.6m / Invested Capital 2.01b)
WACC = 7.26% (E(1.15b)/V(2.40b) * Re(11.45%) + D(1.25b)/V(2.40b) * Rd(4.98%) * (1-Tc(0.32)))
Discount Rate = 11.45% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -55.28 | Cagr: -0.33%
[DCF] Terminal Value 75.44% ; FCFF base≈178.0m ; Y1≈178.8m ; Y5≈189.4m
[DCF] Fair Price = 84.73 (EV 2.95b - Net Debt 1.07b = Equity 1.87b / Shares 22.1m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: -94.81 | EPS CAGR: -61.80% | SUE: 0.0 | # QB: 0
Revenue Correlation: -82.69 | Revenue CAGR: -3.16% | SUE: -1.37 | # QB: -2
EPS current Quarter (2026-12-31): EPS=0.01 | Chg30d=+110.37% | Revisions=+25% | Analysts=5
EPS current Year (2026-09-30): EPS=0.71 | Chg30d=-4.24% | Revisions=+0% | GrowthEPS=+16.6% | GrowthRev=-4.9%
EPS next Year (2027-09-30): EPS=1.57 | Chg30d=-3.95% | Revisions=-10% | GrowthEPS=+121.3% | GrowthRev=+4.4%
[Analyst] Revisions Ratio: +0% (up=8, down=8)